We investigated the impact of human epidermal growth factor receptor 2 (HER2) and prognostic factors in the outcome of patients with breast cancer that developed brain metastases.
Methods
The data from 94 patients who received multidisciplinary therapy from 2001 to 2007 were retrospectively reviewed. Patients were assigned according to their HER2 status, and overall survival and time to brain metastases recurrence/progression were evaluated. The prognostic value of age, presence of extracerebral metastases, recursive partitioning analysis class, hormone therapy, systemic therapy and trastuzumab was assessed.
Results
The median overall survival and time to brain disease progression were 7.1 and 6.5 months, respectively. HER2 positivity (P = 0.006), treatment with trastuzumab (P = 0.025), chemotherapy (P = 0.011) and recursive partitioning analysis class I-II (P <0.001) were associated with prolonged survival on univariate analysis. On multivariate analysis, only recursive partitioning analysis class I-II (P <0.001) and triple-negative disease (P = 0.04) remained significant for overall survival, whereas time to brain metastases progression was only associated with recursive partitioning analysis class I-II (P = 0.001). The time from the diagnosis of primary disease to brain metastasis was slightly shorter in the HER2+ patients than in HER2– patients (36 vs 39 months). Intensified local treatment of brain metastasis incorporating whole-brain radiotherapy and/or radiosurgery and neurosurgery did not affect survival. Patients with triple-negative disease presented a significantly lower survival than the rest of the cohort (4 vs 8 months; P = 0.012).
Conclusions
Recursive partitioning analysis class I-II was found to be the strongest independent predictive factor. Treatment with trastuzumab in HER2+ patients appeared to improve overall survival, probably due to the better control of systemic metastatic disease, but did not maintain significance in multivariate analysis. The dismal prognosis of patients with triple-negative breast cancer highlights the need to develop novel therapies to improve the poor survival.
BoogerdW., VosV.W., HartA.A., BarisG.: Brain metastases in breast cancer; natural history, prognostic factors and outcome.J Neurooncol, 15: 165–174, 1993.
2.
LentzschS., ReichardtP., WeberF., BudachV., DorkenB.: Brain metastases in breast cancer: Prognostic factors and management.Eur J Cancer, 35: 580–585, 1999.
3.
PienkowskiT., ZielinskiC.C.: Trastuzumab treatment in patients with breast cancer and metastatic cns disease.Ann Oncol, 21: 917–924, 2010.
4.
ChargariC., CampanaF., PiergaJ.Y., VedrineL., RicardD., Le MoulecS., FourquetA., KirovaY.M.: Whole-brain radiation therapy in breast cancer patients with brain metastases.Nat Rev Clin Oncol, 7: 632–640, 2010.
5.
OwensM.A., HortenB.C., Da SilvaM.M.: Her2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.Clin Breast Cancer, 5: 63–69, 2004.
6.
CioccaD.R., FujimuraF.K., TandonA.K., ClarkG.M., MarkC., Lee-ChenG.J., PoundsG.W., VendelyP., OwensM.A., PandianM.R., McGuireW.: Correlation of her-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers.J Natl Cancer Inst, 84: 1279–1282, 1992.
7.
MeliskoM.E., GlantzM., RugoH.S.: New challenges and opportunities in the management of brain metastases in patients with erbb2-positive metastatic breast cancer.Nat Clin Pract Oncol, 6: 25–33, 2009.
8.
von MinckwitzG., du BoisA., SchmidtM., MaassN., CuferT., de JonghF.E., MaartenseE., ZielinskiC., KaufmannM., BauerW., BaumannK.H., ClemensM.R., DuerrR., UleerC., AnderssonM., SteinR.C., NekljudovaV., LoiblS.: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A german breast group 26/breast international group 03–05 study.J Clin Oncol, 27: 1999–2006, 2009.
9.
ShmueliE., WiglerN., InbarM.: Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment.Eur J Cancer, 40: 379–382, 2004.
10.
LindrudS., OrlickM., BarnardN., HaitW.N., ToppmeyerD.L.: Central nervous system progression during systemic response to trastuzumab, humanized anti-her-2/neu antibody, plus paclitaxel in a woman with refractory metastatic breast cancer.Breast J, 9: 116–119, 2003.
11.
Mahmoud-AhmedA.S., SuhJ.H., LeeS.Y., CrownoverR.L., BarnettG.H.: Results of whole brain radiotherapy in patients with brain metastases from breast cancer: A retrospective study.Int J Radiat Oncol Biol Phys, 54: 810–817, 2002.
12.
BoogerdW., HartA.A., TjahjaI.S.: Treatment and outcome of brain metastasis as first site of distant metastasis from breast cancer.J Neurooncol, 35: 161–167, 1997.
13.
AoyamaH.Radiation therapy for brain metastases in breast cancer patients.Breast Cancer, 18: 244–251, 2011.
14.
KasedN., BinderD.K., McDermottM.W., NakamuraJ.L., HuangK., BergerM.S., WaraW.M., SneedP.K.: Gamma knife radiosurgery for brain metastases from primary breast cancer.Int J Radiat Oncol Biol Phys, 75: 1132–1140, 2009.
15.
KasedN., HuangK., NakamuraJ.L., SahgalA., LarsonD.A., McDermottM.W., SneedP.K.: Gamma knife radiosurgery for brainstem metastases: The UCSF experience.J Neurooncol, 86: 195–205, 2008.
16.
MuacevicA., KrethF.W., TonnJ.C., WowraB.: Stereotactic radiosurgery for multiple brain metastases from breast carcinoma.Cancer, 100: 1705–1711, 2004.
17.
GasparL.E., ScottC., MurrayK., CurranW.: Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases.Int J Radiat Oncol Biol Phys, 47: 1001–1006, 2000.
18.
FokasE., HenzelM., HammK., SurberG., KleinertG., Engenhart-CabillicR.: Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery?: Analysis of 88 patients.Strahlenther Onkol, 186: 210–217, 2010.
19.
FokasE., WackerU., GrossM.W., HenzelM., EnchevaE., Engenhart-CabillicR.: Hypofractionated stereotactic reirradiation of recurrent glioblastomas: a beneficial treatment option after high-dose radiotherapy?Strahlenther Onkol, 185: 235–240, 2009.
20.
HenzelM., GrossM.W., HammK., SurberG., KleinertG., FailingT., StrassmannG., Engenhart-CabillicR.: Significant tumor volume reduction of meningiomas after stereotactic radiotherapy: results of a prospective multicenter study.Neurosurgery, 59: 1188–1194, 2006.
21.
FokasE., HenzelM., HammK., SurberG., KleinertG., Engenhart-CabillicR.: Multidisciplinary treatment of brain metastases derived from colorectal cancer incorporating stereotactic radiosurgery: analysis of 78 patients.Clin Colorectal Cancer, 10: 121–125, 2011.
22.
ShawE., ScottC., SouhamiL., DinapoliR., KlineR., LoefflerJ., FarnanN.: Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90–05.Int J Radiat Oncol Biol Phys, 47: 291–298, 2000.
23.
NamB.H., KimS.Y., HanH.S., KwonY., LeeK.S., KimT.H., RoJ.: Breast cancer subtypes and survival in patients with brain metastases.Breast Cancer Res, 10: R20, 2008.
24.
EichlerA.F., KuterI., RyanP., SchapiraL., YoungerJ., HensonJ.W.: Survival in patients with brain metastases from breast cancer: The importance of HER-2 status.Cancer, 112: 2359–2367, 2008.
25.
WolstenholmeV., HawkinsM., AshleyS., TaitD., RossG.: Her2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients.Breast, 17: 661–665, 2008.
26.
ChurchD.N., ModgilR., GuglaniS., BahlA., HopkinsK., BraybrookeJ.P., BlairP., PriceC.G.: Extended survival in women with brain metastases from HER2 overexpressing breast cancer.Am J Clin Oncol, 31: 250–254, 2008.
27.
MeliskoM.E., MooreD.H., SneedP.K., De FrancoJ., RugoH.S.: Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival.J Neurooncol, 88: 359–365, 2008.
28.
NiwinskaA., MurawskaM., PogodaK.: Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT).Ann Oncol, 21: 942–948, 2010.
29.
NiwinskaA., MurawskaM., PogodaK.: Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases.Cancer, 116: 4238–4247, 2010.
30.
AndersC.K., DealA.M., MillerC.R., KhorramC., MengH., BurrowsE., LivasyC., FritchieK., EwendM.G., PerouC.M., CareyL.A.: The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.Cancer, 117: 1602–1611, 2011.
31.
MusolinoA., CiccolalloL., PanebiancoM., FontanaE., ZanoniD., BozzettiC., MichiaraM., SiliniE.M., ArdizzoniA.: Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.Cancer, 117: 1837–1846, 2011.
32.
BartschR., FrommS., RudasM., WenzelC., HarbauerS., RoesslerK., KitzK., StegerG.G., WeitmannH.D., PoetterR., ZielinskiC.C., DieckmannK.: Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer - a retrospective analysis.Radiother Oncol, 80: 313–317, 2006.
33.
DawoodS., Gonzalez-AnguloA.M., AlbarracinC., YuT.K., HortobagyiG.N., BuchholzT.A., WoodwardW.A.: Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review.Cancer, 116: 3084–3092, 2010.
34.
FrommS., BartschR., RudasM., de VriesA., WenzelC., StegerG.G., ZielinskiC.C., PoetterR., DieckmannK.: Factors influencing the time to development of brain metastases in breast cancer.Breast, 17: 512–516, 2008.
35.
MeliskoM.E., KunwarS., PradosM., BergerM.S., ParkJ.W.: Brain metastases of breast cancer.Expert Rev Anticancer Ther, 5: 253–268, 2005.
36.
BoogerdW., DalesioO., BaisE.M., van der SandeJ.J.: Response of brain metastases from breast cancer to systemic chemotherapy.Cancer, 69: 972–980, 1992.
37.
CocconiG., LotticiR., BisagniG., BacchiM., TonatoM., PassalacquaR., BoniC., BelsantiV., BassiP.: Combination therapy with platinum and etoposide of brain metastases from breast carcinoma.Cancer Invest, 8: 327–334, 1990.
38.
WangM.L., YungW.K., RoyceM.E., SchomerD.F., TheriaultR.L.: Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer.Am J Clin Oncol, 24: 421–424, 2001.
39.
LedermanG., WronskiM., FineM.: Fractionated radiosurgery for brain metastases in 43 patients with breast carcinoma.Breast Cancer Res Treat, 65: 145–154, 2001.
CareyL., WinerE., VialeG., CameronD., GianniL.: Triple-negative breast cancer: disease entity or title of convenience?Nat Rev Clin Oncol, 7: 683–692, 2010.
